Menu Close

PGMBM Calls On Bayer To Address Global Claims After US Settlement In Essure Case

Thousands of claims have now been settled in the USA surrounding the controversial Essure implant, but PGMBM is still fighting for justice for thousands of other victims.

While the $1.6 billion settlement decision in the US is welcomed, PGMBM is still helping the many UK victims who are awaiting justice after years of suffering with chronic pelvic or lower abdominal pain, abnormal uterine bleeding and allergic or autoimmune complications.

Harris Pogust, PGMBM Partner, called Essure ‘one of the most dangerous medical devices that has been put on the market in recent memory’ and asked for Bayer to be held accountable.

“Bayer was aware of the risks of severe complications but intentionally failed to inform the public, he said.

“When the truth came out, Bayer took Essure off of the market but that was too late for the hundreds of thousands of women affected. Now, Bayer has decided to compensate women in the United States for its incomprehensible conduct. Do women in the UK not feel the same pain? Have they not endured the same suffering?

“It’s time for Bayer to be held to account and to compensate the thousands of women in the UK who have suffered avoidable pain and suffering.”

What is Essure?

It is estimated that 100,000 women in the UK have been fitted with an Essure implant, a device made available by the NHS and administered in GP surgeries from 2002 to 2017.

It was offered as a non-surgical alternative to traditional sterilisation methods, but many women who had it fitted have been left in crippling pain and facing limited treatment options.

Many women have had to endure multiple surgeries to remove Essure, a complex procedure that often calls for a total hysterectomy.

If you have been affected by Bayer’s negligence, please contact us to join us in our fight for justice and receive the compensation you deserve.

Find out more about the ongoing Essure case. 

Share this story

More Stories

Wall Street Journal publishes report highlighting effects of EzriCare Artificial Tears Eye Drops

Pogust Goodhead is currently litigating against the manufacturers of EzriCare and Delsam Pharma’s Artificial Tears in the US, and, this week, the Wall Street Journal has published a feature on the lawsuit and our client, Beverly Jennings.

READ MORE

NHS England publishes new guidance for Gender Incongruence treatment centres

On 9 June 2023, NHS England published an interim service specification which outlines the aims of Gender Incongruence treatment services and the clinical approaches to treatment which should be adopted going forwards.

READ MORE

Pogust Goodhead sponsor Brazil Forum UK 2023

Over the weekend, the Pogust Goodhead team had the pleasure of joining the 2023 Brazil Forum UK held at the University of Oxford.

READ MORE
This site is registered on wpml.org as a development site.